Alcoholic hepatitis treatment market

Alcoholic hepatitis is a serious, inflammatory condition of the liver caused by excessive alcohol consumption over time. It is often exacerbated by heavy drinking and long-term alcohol use. Due to continuous drinking, some additional complications may occur in body such as cirrhosis, excessive bleeding, and even liver failure. When the liver is harmed, as a result of decades of heavy drinking, it can become inflamed, scarred, and fatty, and eventually may stop working properly. For instance, according to the American Liver Foundation 2017, alcoholic hepatitis affects only a small percentage of heavy drinkers in the U.S. that is not over 35%.

The common symptoms of alcoholic hepatitis include pain and swelling in abdomen, fatigue, weight loss, jaundice, nausea & vomiting, fever, easy bleeding, and bruising.

If the alcoholic hepatitis is mild, stopping consumption of alcohol may help in reversing the disease. Changing the diet, which include intake of low-sodium foods along with diuretics and vitamin supplements, could be another form of treatment. Medication that reduces inflammation in the liver and improves liver function such as corticosteroids (pentoxifylline) may be used to treat alcoholic hepatitis. If the above-mentioned treatments do not work, owing to the disease progression, a liver transplant may be required.

Global Alcoholic Hepatitis Treatment Market – Dynamics

The rising cases of alcohol use and deaths due to alcoholic hepatitis are expected to propel the growth of global alcoholic hepatitis treatment market over the forecast period. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2018, 25.1% of adults aged 18 and above had at least one heavy drinking day (five or more drinks for men and four or more drinks for women) in the U.S. Moreover, in 2019, 24,110 people died as a result of alcoholic liver disease in the U.S.

Moreover, increasing product launches and approvals is expected to boost global alcoholic hepatitis treatment market growth. For instance, on December 16, 2020, Durect Corporation announced that DUR-928 was granted fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of alcoholic hepatitis. Durect is a biopharmaceutical company dedicated to transforming the treatment of acute organ injury and chronic liver diseases through the development of novel, potentially lifesaving therapies. DUR-928, Durect's lead drug candidate, is an endogenous sulfated oxysterol and an epigenetic regulator with a distinct mechanism of action. Epigenetic regulators are compounds that control gene expression patterns without altering the DNA sequence. These factors are expected to support global alcoholic hepatitis treatment market growth over the forecast period.

Global Alcoholic Hepatitis Treatment Market – Regional Insights

Among regions, North America is expected to account for the largest share in global alcoholic hepatitis treatment market over the forecast period, owing to the continuous research and development activities for the treatment of alcoholic hepatitis. For instance, on November 13, 2019, researchers at University of California San Diego School of Medicine located in the U.S. released a statement regarding Bacteriophages as a potential treatment for alcoholic liver hepatitis. It was found that bacteriophages clears the bacterial infections and helps eliminating alcoholic liver disease in mice. These factors are expected to support global alcoholic hepatitis treatment market growth over the forecast period.

Global Alcoholic Hepatitis Treatment Market    – Taxonomy

By Drug Class:

• Corticosteroids
• Hemorheologic Agents
• Monoclonal Antibodies
• Anabolic Steroids
• Others

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa

Global Alcoholic Hepatitis Treatment Market – Competitive landscape

Key players operating in the global alcoholic hepatitis treatment market include Apotex Inc., Gilead Sciences Inc., Johnson & Johnson Services Inc., Alkermes plc , Mallinckrodt Pharmaceuticals, Durect Corporation , Novartis AG, Teva Pharmaceutical Industries Ltd., Aventis Pharma Ltd., and Cipla Ltd.